Top news of the week: 12.05.2020.
Medicine, Agaricus bisporus, Biotechnology, Multiple sclerosis, Mental health, Demography
Healthcare
RT @matthewherper: Prominent Broad Institute scientist leaves to lead R&D at Genentech https://t.co/1Ysv4ObffQ
OpenProminent Broad Institute scientist leaves to lead R&D at Genentech
Aviv Regev, a core institute member of the Broad Institute of MIT and Harvard, will become head of Genentech research and early development on Aug. 1.
The Biotech Boom Looking To Rival Cannabis #BioTech via https://t.co/2sI0UxJbpn https://t.co/1jWcmOUeRX
OpenThe Biotech Boom Looking To Rival Cannabis
Millions across the globe are struggling with their mental health, and the COVID-19 pandemic is compounding a crisis that has been ignored throughout history. The U.S. alone spent $89 ...
2020’s Biotech Boom Has Only Just Begun #BioTech via https://t.co/2sI0UxJbpn https://t.co/qa4sXWorvE
Open2020’s Biotech Boom Has Only Just Begun
A promising new mental health treatment has recently been fast-tracked by the FDA, and it stands to kickstart a new biotech industry
AI tool spots 59 possible COVID-19 drugs in UK Biobank data - https://t.co/dKg78j8h6S #AI #pharma
OpenAI tool spots 59 possible COVID-19 drugs in UK Biobank data
Scientists at UK biotech PrecisionLife say they have used the UK Biobank to identify human genes that can
Chutes & Ladders—Johnson & Johnson elevates Khan to data science officer role https://t.co/fDns2VOWfJ https://t.co/lqqxVggA51
OpenChutes & Ladders—Johnson & Johnson elevates Khan to data science officer role
Johnson & Johnson taps Khan for chief data role; Icon poaches AstraZeneca vet Buck as CMO; Intellia signs on Lebwohl as CMO.
Biopharma Update on the Novel Coronavirus: May 6 https://t.co/pCdY9MXbUn https://t.co/qR4aPhDjQu
OpenBiopharma Update on the Novel Coronavirus: May 6
Please check out the biopharma industry coronavirus (COVID-19) stories that are trending for May 6, 2020.
Months after closing $617M life sciences fund, Frazier Healthcare nabs biopharma vets https://t.co/SsHJ6pDRDZ https://t.co/A8LBqoIw9F
OpenMonths after closing $617M life sciences fund, Frazier Healthcare nabs biopharma vets
Venture capital firm Frazier Healthcare has grabbed Scott Byrd, Ian Mills, and Gordon McMurray as its new Entrepreneur-in-Residence consultants.
After Alexion buyout, ex-Achillion nephrology lead jumps ship to Gemini Therapeutics https://t.co/N1iOsbERgC
OpenAfter Alexion buyout, ex-Achillion nephrology lead jumps ship to Gemini Therapeutics
Just a few months after Alexion snapped up complement inhibitor biotech Achillion, Gemini Therapeutics has nabbed one of its key R&D execs as its new chief medical officer.